Xu Ting, Du Xiao-Wen, Hu Jun-Biao, Zhu Yong-Feng, Wu Hui-Ling, Dai Guo-Ping, Shu Yao-Min, Ouyang Jun
Department of Urology, Jinhua People's Hospital, Jinhua, Zhejiang 321000, P.R. China.
Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China.
Oncol Lett. 2018 Mar;15(3):3814-3819. doi: 10.3892/ol.2018.7745. Epub 2018 Jan 8.
The present study aimed to investigate the role of microRNA-96 (miR-96) in the proliferation, invasion and apoptosis of bladder cancer cell lines, and the associated mechanisms. The expression of miR-96 and human ether-à--related (HERG1) potassium channel in the normal uroepithelium SV-HUC-1 cell line, and bladder cancer T24 and 5637 cell lines were examined using reverse transcription-polymerase chain reaction or/and western blotting. Transfection with miR-96 inhibitor or scrambled control (SC) was used to study the biological activities of miR-96 in bladder cancer cell lines. MTT, flow cytometric and Transwell assays were applied to detect cell viability, apoptosis and invasion, respectively. A dual-luciferase reporter assay was applied to determine the association between miR-96 and HERG1 expression. As demonstrated, miR-96 was highly expressed in the two bladder cancer cell lines, particularly in T24 cells. Following transfection with miR-96 inhibitor, miR-96 expression was significantly reduced in the T24 cell line, compared with SC. The miR-96 inhibitor suppressed cell proliferation and invasion, promoted apoptosis and arrested the cell cycle at the G phase. Consistently, HERG1 was also highly expressed in the two bladder cancer cell lines at the mRNA and protein level, but not in the normal uroepithelium cell line. The miR-96 inhibitor also significantly decreased HERG1 expression compared with SC. The results of the dual-luciferase reporter assay indicated that miR-96 directly targeted wild-type HERG1. In conclusion, miR-96 inhibitor exhibited anticancer effects on bladder cancer cells by inhibiting proliferation and invasion of cells, and promoting their apoptosis. HERG1 was an important target of miR-96. These results provided experimental evidence supporting miR-96 as a therapeutic target for patients with bladder cancer.
本研究旨在探讨微小RNA-96(miR-96)在膀胱癌细胞系增殖、侵袭和凋亡中的作用及其相关机制。采用逆转录-聚合酶链反应或/和蛋白质印迹法检测正常尿路上皮SV-HUC-1细胞系以及膀胱癌细胞T24和5637细胞系中miR-96和人醚-à-相关基因(HERG1)钾通道的表达。通过转染miR-96抑制剂或乱序对照(SC)来研究miR-96在膀胱癌细胞系中的生物学活性。分别应用MTT法、流式细胞术和Transwell实验检测细胞活力、凋亡和侵袭情况。采用双荧光素酶报告基因检测法确定miR-96与HERG1表达之间的关联。结果显示,miR-96在两种膀胱癌细胞系中高表达,尤其是在T24细胞中。与SC相比,用miR-96抑制剂转染后,T24细胞系中miR-96表达显著降低。miR-96抑制剂抑制细胞增殖和侵袭,促进凋亡,并使细胞周期停滞在G期。同样,HERG1在两种膀胱癌细胞系的mRNA和蛋白质水平也高表达,但在正常尿路上皮细胞系中不表达。与SC相比,miR-96抑制剂也显著降低了HERG1的表达。双荧光素酶报告基因检测结果表明,miR-96直接靶向野生型HERG1。综上所述,miR-96抑制剂通过抑制膀胱癌细胞的增殖和侵袭以及促进其凋亡,对膀胱癌细胞具有抗癌作用。HERG1是miR-96的重要靶点。这些结果为miR-96作为膀胱癌患者的治疗靶点提供了实验证据。